YEARS OF EXCELLENCE IN RESEARCH



BA-BE & PHASE-I CAPABILITIES

EXPERIENCE

- Extensive experience in Phase I Trials
- FIH, SAD/MAD, BA/BE, DDI, Food Effect, PK/PD
- Population: Male, Female, Elderly Male, Post Menopausal, Children (US) & Special population

Type of Study	Location	# of Studies
Bioavailability & Bioequivalence (BA/BE)	India/NA	6000+
First-in-human(FIH)	India/NA	31
Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)	India/NA	27
Drug-Drug interaction(DDI)	India/NA	24
PK/PD	India/NA	23
Food Effect	India/NA	15
Skin Blanching	NA	100+
Transdermal Delivery Systems Studies	India/NA	200+

CAPABILITIES

CLIANTHA	RESEARCH,
INDIA	

Locations: Ahmedabad, Noida, Vadodara 4 Clinical Units, 718 Beds, 24 ICU Beds

20 Bed Phase I unit

Central Lab accredited by CAP & NABL 73,000+ healthy subjects database

CLIANTHA RESEARCH,

Locations: St. Petersburg, FL

48 Beds

Local Central Laboratory

Secured pharmacy with DEA license for schedule 2, 2N, 3, 4 and 5

CLIANTHA RESEARCH, CANADA

Locations: Mississauga, ON

2 combinable units with 60 Beds

1 ICU Phase I unit with 8 Beds

Access to special population in respiratory diseases

Environmental Exposure Chambers for Allergy and

Dry Eye



EXPERIENCE WITH ROUTE OF ADMINISTRATION

Oral [5500+]

- Tablet (IR, ER, SR, MR, CR, DR, ODT, Chewable)
- Capsules
- Chewable Tablets
- Suspension
- Granules
- Sublingual

Injection [40+]

Dermal [170+]


- Ointment
- Cream
- Patch
- Gel

Pulmonary [15+]

- Nasal Spray
- MDI
- DPI

Rectal [5+]

Vaginal [10+]



REGULATORY EXPERIENCE

- 56 Clinical Audits (USA: 10, Canada: 10, India: 36)
- Experience in studying FIH in patients & special population
- Successful track record of Scientific, Clinical & Medical interactions with regulatory authorities and ethics committees
- Team has experience in presenting to Health Canada & USFDA for approval of studies
- In-house preparation of Clinical Trial Application and IRB package